Subscribe To
Cargo therapeutics begins $100 million ipo rollout
Cargo Therapeutics, Inc. has filed for a $100 million IPO to develop improved CAR T-cell therapy for large B-cell lymphoma. The company's lead candida...
October 23, 2023, 5:47 pm
diffuse ceo kenny estes explains what led to bitcoin’s big drop
diffuse CEO Kenny Estes weighs in on what could have caused bitcoin’s big drop last week and describe...
August 23, 2023, 8:44 pm
Regeneron's (regn) application for blood cancer drug accepted
Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or ...
August 18, 2023, 2:05 pm
Adc therapeutics (adct) dips on halting zynlonta study
ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously...
July 12, 2023, 11:49 am
Genmab: epkinly's approval not big enough needle-mover (neutral)
Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory ...
June 29, 2023, 10:05 am
Roche (rhhby) gets fda approval for blood cancer drug columvi
Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (...
June 16, 2023, 1:51 pm
Nurix therapeutics presents data from studies of its targeted protein degraders in b cell malignancies and initiates expansion of nx-2127 phase 1b trial in diffuse large b cell lymphoma and mantle cel
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) ...
June 14, 2023, 11:00 am
Spirit 48: long des for diffuse cad highly deliverable, safe at 1 year
Imaging wasn’t mandated, but it could help better differentiate patients for whom the device is a good fit, says Ki Park. Read Full Story at source ...
May 31, 2023, 5:59 pm
Sunset market commentary
Markets After a brief rebound yesterday, yields again turned south today. Growth and inflation data published in several EMU member states understanda...
April 28, 2023, 2:09 pm
Roche (rhhby) polivy combo backed by fda advisory committee
Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated ...
March 10, 2023, 1:47 pm
Fda committee backs roche's lymphoma treatment
A U.S. Food and Drug Administration committee voted in favor of Roche Holding AG's Polivy antibody drug targeting untreated ...
March 10, 2023, 2:10 am
Aromatherapy market worth usd 10.5 billion by 2030 at 10.10% cagr – report by market research future (mrfr)
Aromatherapy Market Research Report Trends and Insights Information By Product (Essential Oil, Carrier Oils And Blended Oils), Equipment (Nebulizer ...
March 7, 2023, 2:30 pm
Roche's phase 3 data show lymphoma treatment can reduce disease risks
Roche Holding AG presented new data from a Phase 3 study showing that its Polivy antibody-drug can significantly reduce the risk of disease deteriorat...
December 12, 2022, 2:24 am
Sunset market commentary
Markets Yesterday’s (perceived) soft speech of Fed chair Powell (slowing the pace of rate hikes to 50 bps in December) at that time triggered a shar...
December 1, 2022, 3:16 pm
Midatech pharma boosted by european news on key product
Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Me...
June 21, 2022, 4:01 am
Fate: possible speedy fda approval process with rmat designation
Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory ...
June 3, 2022, 12:52 pm
Gamida cell shares jump on fda nod to cell therapy trial in blood cancer settings
The FDA has signed off and removed the clinical hold for a cryopreserved formulation of Gamida Cell Ltd's (NASDAQ: GMDA) GDA-201, an off-the-shelf...
April 26, 2022, 9:33 am
Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...
February 1, 2022, 10:03 am
Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...
February 1, 2022, 10:03 am
Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...
February 1, 2022, 10:03 am